CLOROQUINA E HIDROXICLOROQUINA COMO OPÇÕES PARA TRATAR A COVID-19

CHLOROCHINE AND HYDROXYCHLOROCHINE AS OPTIONS TO TREAT COVID-19

Autores

  • Maria Luana de Freitas Rabelo Graduanda em Farmácia pela Universidade Federal do Ceará (UFC).

Downloads

Não há dados estatísticos.

Referências

Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–60.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet [Internet]. 2020;395(10224):565–74. Disponível em: <http://dx.doi.org/10.1016/S0140-6736(20)30251-8>.

Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–6.

Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients with COVID-19. JAMA - J Am Med Assoc. 2020;323(15):1499–500.

Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source . These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active . The anti-viral facet of anti-rheumatic drugs : Lessons from COVID-19. 2020;(January).

Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol [Internet]. 2020;16(3):155–66. Disponível em: <http://dx.doi.org/10.1038/s41584-020-0372x>.

Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf. 2018;41(10):919–31.

Al-Bari AA. Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2014;70(6):1608–21.

Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet (London, England) [Internet]. 2020;6736(20):1–10. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/32450107>.

Downloads

Publicado

22-07-2020

Como Citar

1.
de Freitas Rabelo ML. CLOROQUINA E HIDROXICLOROQUINA COMO OPÇÕES PARA TRATAR A COVID-19: CHLOROCHINE AND HYDROXYCHLOROCHINE AS OPTIONS TO TREAT COVID-19. Cadernos ESP [Internet]. 22º de julho de 2020 [citado 29º de março de 2024];14(1):176-7. Disponível em: https://cadernos.esp.ce.gov.br/index.php/cadernos/article/view/371
Received 2020-05-30
Accepted 2020-07-22
Published 2020-07-22